|Articles|May 17, 2021
Disruption without interruption: Transitioning Rare Disease HUB & NCP Programs
Author(s)RareMed Solutions
Transitioning a rare disease HUB or NCP program to a rare-focused partner can yield major service quality improvements without program disruption.
Advertisement
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
WeightWatchers to Offer Novo Nordisk’s Oral Wegovy, if Approved Next Year
2
Pharma Pulse: FDA Advances New Approval Pathway, as Obesity Care and Metabolic Treatments Gain Momentum
3
Pharma Pulse: FDA Appoints Richard Pazdur as CDER Director Amid 340B Tensions and Novartis Expansion
4
Novartis Expands US Footprint With New Radioligand Therapy Manufacturing Facility in California
5
